Suppr超能文献

关于2019冠状病毒病发病机制、临床表现及现有治疗方法的综述,重点关注血管紧张素转换酶2。

Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2.

作者信息

Rathi Himani, Burman Vishakha, Datta Sudip Kumar, Rana Satya Vati, Mirza Anissa Atif, Saha Sarama, Kumar Raman, Naithani Manisha

机构信息

Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand India.

Department of Biotechnology, SVBP University of Agriculture and Technology, Meerut, Uttar Pradesh India.

出版信息

Indian J Clin Biochem. 2021 Jan;36(1):3-22. doi: 10.1007/s12291-020-00953-y. Epub 2021 Jan 3.

Abstract

In December 2019, Wuhan city in the Hubei province of China reported for the first time a cluster of patients infected with a novel coronavirus, since then there has been an outburst of this disease across the globe affecting millions of human inhabitants. Severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), is a member of beta coronavirus family which upon exposure caused a highly infectious disease called novel coronavirus disease-2019 (COVID-19). COVID-19, a probably bat originated disease was declared by World Health Organization (WHO) as a global pandemic in March 2020. Since then, despite rigorous global containment and quarantine efforts, the disease has affected nearly 56,261,952 laboratory confirmed human population and caused deaths of over 1,349,506 lives worldwide. Virus passes in majority through respiratory droplets and then enters lung epithelial cells by binding to angiotensin converting enzyme 2 (ACE2) receptor and there it undergoes replication and targeting host cells causing severe pathogenesis. Majority of human population exposed to SARS-CoV-2 having fully functional immune system undergo asymptomatic infection while 5-10% are symptomatic and only 1-2% are critically affected and requires ventilation support. Older people or people with co-morbidities are severely affected by COVID-19. These categories of patients also display cytokine storm due to dysfunctional immune response which brutally destroys the affected organs and may lead to death in some. Real time PCR is still considered as standard method of diagnosis along with other serology, radiological and biochemical investigations. Till date, no specific validated medication is available for the treatment of COVID-19 patients. Thus, this review provides detailed knowledge about the different landscapes of disease incidence, etiopathogenesis, involvement of various organs, diagnostic criteria's and treatment guidelines followed for management of COVID-19 infection since its inception. In conclusion, extensive research to recognize novel pathways and their cross talk to combat this virus in precarious settings is our future positive hope.

摘要

2019年12月,中国湖北省武汉市首次报告了一群感染新型冠状病毒的患者,自那时起,这种疾病在全球爆发,影响了数百万人类居民。严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)是β冠状病毒家族的成员,一经接触就会引发一种名为2019年新型冠状病毒病(COVID-19)的高度传染性疾病。COVID-19可能起源于蝙蝠,2020年3月,世界卫生组织(WHO)宣布其为全球大流行疾病。从那时起,尽管全球进行了严格的防控和隔离措施,但该疾病已影响了近56261952例实验室确诊的人群,并在全球范围内导致超过1349506人死亡。病毒大多通过呼吸道飞沫传播,然后通过与血管紧张素转换酶2(ACE2)受体结合进入肺上皮细胞,并在那里进行复制并靶向宿主细胞,从而导致严重的发病机制。大多数接触SARS-CoV-2且免疫系统功能正常的人会发生无症状感染,而5%-10%的人会出现症状,只有1%-2%的人受到严重影响,需要通气支持。老年人或患有合并症的人受COVID-19的影响更为严重。这些患者类别还会因免疫反应功能失调而出现细胞因子风暴,这会残酷地破坏受影响的器官,在某些情况下可能导致死亡。实时荧光定量聚合酶链反应(Real time PCR)与其他血清学、放射学和生化检查一起,仍被视为标准的诊断方法。迄今为止,尚无针对COVID-19患者的特效验证药物。因此,本综述详细介绍了自COVID-19感染开始以来,其疾病发病率、病因发病机制、各个器官的受累情况、诊断标准以及治疗指南等不同方面的知识。总之,开展广泛研究以识别新的途径及其相互作用,从而在不稳定的情况下对抗这种病毒,是我们未来积极的希望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccd8/7817724/6292c4ad5649/12291_2020_953_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验